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lenges and opportunities. Results: Only 22%-27% of payers and providers believe 
that personalized medicine is a “very important” strategic goal versus ~50% of large 
biopharma manufacturers. Although 47%-52% of all stakeholders have integrated 
staff with area expertise, fewer than 20% have developed a centralized focus on 
personalized medicine and only 8%-20% believe they have tools to evaluate its suc-
cess. Decision maker perspectives ranged broadly on its key benefits but included 
improved and more predictable outcomes and cost efficiencies. Approximately 30% 
of all stakeholders believe that personalized medicines will continue to receive pre-
mium pricing to justify ROI for this business approach. ConClusions: Although 
most stakeholders see value in personalized medicines, they struggle with practical 
implementation and need actionable strategies to characterize the value and impact 
of these technologies. The survey suggests that limited emphasis on infrastructure 
development and methods, heterogeneous value assessment, and misalignment 
of incentives remain key challenges to enabling care and economic efficiencies 
promised by this evolving treatment paradigm.
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objeCtives: Reliable price data could enable consumers to choose providers that 
offer better value than others, eventually leading to market-level gains in quality 
and efficiency. The objective of this study is to predict price-to-charge ratios (PCRs) 
for community hospital stays on the basis of charge data and information about 
individual stays, hospitals, market areas, and states. Methods: We used 2006 
Healthcare Cost and Utilization Project State Inpatient Databases from California, 
Florida, Massachusetts, Nevada, New Jersey, Virginia, West Virginia and Wisconsin. 
We predicted PCRs for major payer categories for over 1,000 community hospitals 
as a function of state, market, hospital, and patient characteristics using expo-
nential conditional mean models with a log link and gamma-distributed errors. 
The unit of analysis was the hospital. We used a two-stage iterative estimation in 
which equations are estimated individually and the errors saved. In the next step, 
each payer equation is estimated a second time with the first-stage errors of the 
other payer equations as new independent variables. We assessed goodness of fit 
through model characteristics and by assessing the match of actual and predicted 
PCRs. Results: Average demographic characteristics were significant predictors of 
PCRs for Medicare and Private insurance, but not for Medicaid or Self-Pay. Hospital 
characteristics were related to every PCR category. Critical-access hospitals and 
teaching hospitals were associated with significantly greater PCRs for Medicare, 
Medicaid, and Private insurance holders. Greater numbers of Medicare and Medicaid 
discharges were associated with significantly lower PCRs. Higher PCRs were most 
often associated with worse economic conditions and greater state generosity in 
Medicaid eligibility and spending. ConClusions: Inpatient encounter prices paid 
by Medicare, Medicaid, and private insurance can be estimated with acceptable 
accuracy for community hospital stays. Stays funded by other insurance types or 
by patients were harder to predict and simultaneously have almost no correlation 
with PCRs.
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bACkgRound: Over the last decade, evidence-based assessment of food and 
nutritional products has substantially accelerated, in a fast-moving market and 
regulatory environment. Specific evidence synthesis, epidemiological and phar-
maco-economic tools have been increasingly required, developed and used for 
HTA and public health decision support. objeCtives: This presentation high-
lights through case studies the specific needs, tools and challenges arising from 
health economic evaluations of nutritional products. Methods: To first set the 
scene of nutritional product assessment, the regulatory and HTA systems and 
guidelines in both Europe and the US will be described and potential differences 
with drugs or devices highlighted. Through a series of illustrative but representa-
tive case studies covering both health claims and medical nutrition, the specific 
data needs and statistical methods to analyse them will reviewed and discussed. 
Data and methods gaps will be highlighted and consequences on the market 
access strategies and tactics will be discussed. Results: Nutritional products 
would typically target a wider and heterogeneous group of population than 
common drugs. Furthermore, control of food/compound exposure and effect in 
observational and clinical studies is more challenging resulting in larger studies 
and requiring more stringent tracking of compliance. Data analysis then requires 
refined statistical models such as hierarchical models able to handle population 
variability. Safety issues are also expected to be minimal to make benefit/risk 
evaluation acceptable by regulators, so that risk studies and risk management 
tactics should be designed accordingly. Finally, pricing and reimbursement depend 
even more than drugs on how the compound is positioned and for which target 
population. CONCLUSION Standard tools for evidence synthesis and pharmaco-
economic tools applied to nutritional products market access need to be stretched 
to their best to handle the higher population heterogeneity and numerous market 
access options.
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treated as the “intelligence” of the incorporation process procedures in the pub-
lic health system. Efficacy refers to the benefic effect in experimental conditions; 
effectiveness mentions the benefic effect operating under the system’s conditions, 
i.e. the action field; and cost-effectiveness refers to the objective when confronted 
with the costs involved in bringing the procedure into the system. ConClusions: 
The evidence researched by the HTA area, and not individual medical decisions or 
judicial sentences, should lead the policies on public health. The need to study the 
process of judicialization of health through HTA is evident.
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The Association of Southeast Asian Nations or ASEAN consists of ten member 
states. In 2007, the ASEAN leaders determined that the ASEAN Community will be 
established by 2015. The ASEAN Community will become a region with free move-
ment of goods, services, investment, skilled labor, and freer flow of capital. Since 
the trend in medical tourism continues growing worldwide, countries in ASEAN 
are strongly encouraging medical tourism as well. In particular, the Thai govern-
ment is promoting Thailand as a major medical hub in Asia as part of an effort to 
expand and diversify exports. Thailand aims to make itself the leading medical hub 
and the center for medical tourism. In this paper, the establishment of the ASEAN 
Community together with the transformation of Thailand as a medical hub is evalu-
ated. There are some concerns for both Thai and international patients who will 
receive Thai health care services. The increased number of international patients 
from becoming a medical hub along with the forming of the ASEAN Community 
would affect pharmaceutical costs in Thailand and put extra strain on its health 
care system. In addition to the escalated number of foreign patients, the shortage of 
health care professionals and the problem of their distribution in the country would 
be exacerbated. Last, this paper discusses proposed alternatives for the issue. One 
alternative solution that might diminish the effect of rising pharmaceutical costs to 
Thai patients is that the Thai government needs to negotiate with pharmaceutical 
firms producing brand-name medicine on behalf of Thai public hospitals. To reduce 
the shortage of the health care professionals in Thailand, the restrictions on foreign 
health care professionals should be loosened.
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objeCtives: There has been increase in the number of multi-criteria decision analy-
sis (MCDA) applications in health care since 1990s but there is still confusion among 
potential users regarding their appropriate use and this paper reports on an expert 
MCDA meeting organised to address these issues. Methods: An expert meeting 
was held in 2013 in UK with 21 representatives from a variety of governmental, 
academic and pharmaceutical institutes, which had the objective to discuss the 
role, options and limitations of MCDA in health. Results: The key messages and 
good practice recommendations developed by the participants of the expert meeting 
are as follows: a) Problem structuring is key: it is recommended that enough time is 
allocated to understand and specify the decision problem under consideration, b) 
Numerical MCDA modelling is not always necessary: deliberative discourse with the 
performance matrix as a starting point is sufficient in some situations rather than 
numerical MCDA models, c) Variety of weighting and scoring techniques: There are 
a number of different methods to estimate the value scores and to elicit the weights 
but not all scoring methods and weighting techniques are suitable for every MCDA 
method, d) Visualisation/transparency is important: For the decision makers to have 
confidence in the MCDA model, the model outputs need to be adequately visualised 
and the model needs to be transparent, e) Uncertainty modelling: appropriate care 
needs to be taken in performing uncertainty analysis ConClusions: MCDA has 
already been used and is well suited to support a broad range of health care decision 
problems but there is a need to develop a framework to select the appropriate MCDA 
technique for specific health care decisions. Future work is underway to develop 
the guidelines for choosing the most appropriate MCDA method to be applied for a 
given health care decision problem.
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objeCtives: As the US health care system drives toward population-level goals 
for efficiency and effectiveness, demand persists for more personal care at the 
patient-level. Personalized medicine is an emerging business model that harnesses 
genomics and biotechnology aimed at tailoring therapies and interventions to indi-
vidual patient characteristics. Market stakeholders universally acknowledge the 
tectonic shift away from the historic blockbuster drug model to a more targeted 
model. To evaluate current insights and challenges, we surveyed key stakeholders 
and decisions makers across the health care industry. Methods: We conducted a 
survey of approximately 300 biopharma executives, payers, and providers in the US 
and EU to gain insight into their needs, perceptions, and readiness to shift toward 
a more robust personalized medicine approach. This original research is aimed 
to characterize current status of infrastructure, preparedness, adoption and value 
assessment around personalized medicine development and highlight key chal-
